PNH

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Fierce Pharma
Alexion
Soliris
Ultomiris
PNH
Flag link:
Alexion’s Soliris follow-up Ultomiris snares EU approval
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Flag link:
Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria
Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria
Pharmaceutical Business Review
Alexion Pharmaceuticals
Ultomiris
PNH
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Alexion runs toward big Ultomiris goals with early Soliris switching success
Alexion runs toward big Ultomiris goals with early Soliris switching success
Fierce Pharma
Alexion
Ultomiris
paroxysmal nocturnal hemoglobinuria
PNH
Flag link:
Alexion’s newly approved rare-disease drug notches another clinical trial win
Alexion’s newly approved rare-disease drug notches another clinical trial win
Stat
Alexion Pharmaceuticals
clinical trials
Ultomiris
kidney disease
PNH
Flag link:
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
GoinPharma
Alexion
FDA
ALXN1210
Ultomiris
PNH
Flag link:
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Stat
Alexion Pharmaceuticals
FDA
Ultomiris
Soliris
PNH
Flag link:
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Alexion Pharmaceuticals
Alexion
FDA
ALXN210
PNH
paroxysmal nocturnal hemoglobinuria
Flag link:
Alexion's follow-on stacks up to Soliris
Alexion's follow-on stacks up to Soliris
Biopharma Dive
Alexion
Soliris
ALXN1210
paroxysmal nocturnal hemoglobinuria
PNH
Flag link:
Akari CEO resigns amidst dodgy data claims
Akari CEO resigns amidst dodgy data claims
BioPharma Dive
Akari Therapeutics
Pharma CEOs
PNH
clinical trials
Flag link:
The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug
The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug
BioPharma Dive
Soliris
Alnylam
Alexion
PNH
Flag link:
Alnylam Going After World's Most Expensive Drug in New Trials
Alnylam Going After World's Most Expensive Drug in New Trials
Bloomberg
Alnylam
ALN-CC5
Soliris
PNH
Flag link:
The Cure for Alexion
The Cure for Alexion
TheStreet.com
Alexion
PNH
Soliris
Flag link:
Soliris Continues to Drive Growth as Alexion Adds to Its Pipeline
Soliris Continues to Drive Growth as Alexion Adds to Its Pipeline
Morningstar
PNH
Soliris
Alexion
Flag link:
Alexion Hoping Its Soliris Is That Rare Wonder Drug
Alexion Hoping Its Soliris Is That Rare Wonder Drug
Investors.com
Alexion
Soliris
PNH
Flag link:
Alexion: One-Trick Pony, But It's a Pretty Good Trick
Alexion: One-Trick Pony, But It's a Pretty Good Trick
Seeking Alpha
Alexion
Japan
Soliris
PNH
Flag link:
Alexion Accelerates Plans to Launch Soliris® (Eculizumab) in Japan
Alexion Accelerates Plans to Launch Soliris® (Eculizumab) in Japan
Yahoo
Alexion
Japan
Soliris
PNH
Flag link: